Literature DB >> 16294272

Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.

Brian T Feeley1, Seth C Gamradt, Wellington K Hsu, Nancy Liu, Lucie Krenek, Paul Robbins, Johnny Huard, Jay R Lieberman.   

Abstract

UNLABELLED: The purpose of this study was to evaluate the role of BMPs on the formation of metastatic prostate cancer lesions to bone. Our results show that BMPs influence the development and progression of osteoblastic lesions and suggest that therapies that inhibit BMP activity may reduce the formation and progression of osteoblastic lesions.
INTRODUCTION: Prostate adenocarcinoma is the leading cause of cancer in North American men. The formation of skeletal metastases affects approximately 70% of patients with advanced disease, and a majority of these patients have osteoblastic lesions. Although BMPs have been found to be expressed in multiple oncogenic cell lines, their role in the formation of metastatic osteoblastic lesions remains uncharacterized. We hypothesized that BMPs influence the development of metastatic osteoblastic lesions associated with prostate cancer.
MATERIALS AND METHODS: Western blot analysis and RT-PCR was used to determine BMP receptor expression on osteoblastic prostate cancer cell lines LAPC-4 and LAPC-9. Migration, invasion, and cellular proliferation assays were used to quantify the effects of BMP-2, -4, and -7 on LAPC-4 cells in vitro. LAPC-9 cells alone or transfected with a retrovirus overexpressing noggin were injected into the tibias of SCID mice, and the animals were followed for 8 weeks. Tumor size was determined by radiographs and direct measurement. Histology was performed at the time of death.
RESULTS: We determined that BMP receptor mRNA and protein was expressed on osteoblastic prostate cancer cell lines LAPC-4 and LAPC-9. In vitro studies showed that BMP-2 and -7 stimulated cellular migration and invasion of prostate cancer cells in a dose-dependent fashion, although BMP-4 had no effect. Noggin inhibited cellular migration and invasion of BMP-2- and -7-stimulated LAPC-4 cells. LAPC-9 cells implanted into immunodeficient mouse tibias formed an osteoblastic lesion with sclerotic bone at 8 weeks. Formation of osteoblastic lesions was inhibited by overexpression of noggin by prostate cancer cells transduced with a retrovirus containing the cDNA for noggin.
CONCLUSIONS: BMPs are critical in the formation of the osteoblastic lesions associated with prostate cancer metastases, and future treatment strategies that inhibit local BMP activity may reduce the formation and progression of osteoblastic lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16294272     DOI: 10.1359/JBMR.050802

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  45 in total

1.  Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Authors:  Mandeep S Virk; Farhang Alaee; Frank A Petrigliano; Osamu Sugiyama; Arion F Chatziioannou; David Stout; William C Dougall; Jay R Lieberman
Journal:  Bone       Date:  2010-11-10       Impact factor: 4.398

2.  Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect.

Authors:  Sofia Bougioukli; Ashish Jain; Osamu Sugiyama; Brian A Tinsley; Amy H Tang; Matthew H Tan; Douglas J Adams; Paul J Kostenuik; Jay R Lieberman
Journal:  Bone       Date:  2015-12-23       Impact factor: 4.398

3.  Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals.

Authors:  Hikaru Nishimori; Shogo Ehata; Hiroshi I Suzuki; Yoko Katsuno; Kohei Miyazono
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

4.  Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.

Authors:  Ruth Schwaninger; Cyrill A Rentsch; Antoinette Wetterwald; Geertje van der Horst; Rutger L van Bezooijen; Gabri van der Pluijm; Clemens W G M Löwik; Karin Ackermann; Walter Pyerin; Freddie C Hamdy; George N Thalmann; Marco G Cecchini
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

5.  BMP7: a new bone metastases prevention?

Authors:  Pierrick G J Fournier; Theresa A Guise
Journal:  Am J Pathol       Date:  2007-08-09       Impact factor: 4.307

6.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

7.  BMP4 promotes prostate tumor growth in bone through osteogenesis.

Authors:  Yu-Chen Lee; Chien-Jui Cheng; Mehmet A Bilen; Jing-Fang Lu; Robert L Satcher; Li-Yuan Yu-Lee; Gary E Gallick; Sankar N Maity; Sue-Hwa Lin
Journal:  Cancer Res       Date:  2011-06-13       Impact factor: 12.701

8.  Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.

Authors:  Linda Kim Pham; Mengmeng Liang; Helty A Adisetiyo; Chun-Peng Liao; Michael B Cohen; Stanley M Tahara; Baruch Frenkel; Noriyuki Kasahara; Pradip Roy-Burman
Journal:  Endocr Relat Cancer       Date:  2013-11-04       Impact factor: 5.678

Review 9.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

10.  Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1.

Authors:  H-F Yuen; Y-T Chiu; K-K Chan; Y-P Chan; C-W Chua; C M McCrudden; K-H Tang; M El-Tanani; Y-C Wong; X Wang; K-W Chan
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.